# References

## Model-Informed Precision Dosing (MIPD)

1. **Neely MN, et al.** Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? *Antimicrobial Agents and Chemotherapy*. 2014;58(1):309-316.

2. **Rybak MJ, et al.** Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy*. 2009;66(1):82-98.

3. **ASHP/IDSA.** Vancomycin Therapeutic Drug Monitoring Guidelines. *American Journal of Health-System Pharmacy*. 2020.

## Population Pharmacokinetics and Bayesian Forecasting

4. **Sheiner LB, Beal SL.** Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. *Journal of Pharmaceutical Sciences*. 1982;71(12):1344-1348.

5. **Jelliffe R, et al.** Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. *International Journal of Biomedical Computing*. 1993;33(1):55-68.

6. **Neely MN, et al.** Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. *Antimicrobial Agents and Chemotherapy*. 2015;59(6):3090-3097.

7. **Neely MN, et al.** Accurate vancomycin dosing in critically ill patients using a Bayesian approach. *Clinical Pharmacology & Therapeutics*. 2014;95(6):609-616.

## Machine Learning for Dose Prediction

8. **Hongo T, et al.** Machine Learning Approach for Individual Dose Optimization of Vancomycin in Patients with Gram-Positive Infection. *Pharmaceutical Research*. 2020;37(8):157.

9. **Lin H, et al.** Machine Learning to Predict Vancomycin Trough Concentrations: A Systematic Review. *Clinical Pharmacokinetics*. 2021;60(11):1395-1412.

10. **Nielsen EI, et al.** Machine Learning Predicts Vancomycin Steady-State Concentrations in Pediatric Patients. *Clinical Pharmacokinetics*. 2020;59(9):1185-1194.

11. **Sakiyama Y, et al.** Machine learning-based prediction of vancomycin trough concentration in patients with methicillin-resistant Staphylococcus aureus infection. *Journal of Pharmaceutical Health Care and Sciences*. 2021;7(1):1-9.

## Hybrid Approaches

12. **Darwich AS, et al.** Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. *Clinical Pharmacology & Therapeutics*. 2017;101(5):646-656.

13. **Keutzer L, et al.** Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin. *Pharmaceuticals*. 2022;15(2):183.

14. **Vandael E, et al.** Machine Learning for Clinical Decision Support in Infectious Diseases: A Narrative Review of Current Applications. *Clinical Microbiology and Infection*. 2020;26(5):584-595.

## Renal Impairment and Dose Adjustment

15. **Cockcroft DW, Gault MH.** Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31-41.

16. **Levey AS, et al.** A new equation to estimate glomerular filtration rate. *Annals of Internal Medicine*. 2009;150(9):604-612.

17. **Levey AS, et al.** CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Annals of Internal Medicine*. 2009;150(9):604-612.

18. **Matzke GR, et al.** Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney International*. 2011;80(11):1122-1137.

## Vancomycin Dosing

19. **Rybak MJ.** The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clinical Infectious Diseases*. 2006;42 Suppl 1:S35-9.

20. **Lodise TP, et al.** Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. *Clinical Infectious Diseases*. 2009;49(4):507-514.

21. **Prybylski JP.** Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-Analysis of Observational Studies. *Pharmacotherapy*. 2015;35(10):889-898.

22. **Truong J, et al.** Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients with Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review and Recommendations. *Clinical Infectious Diseases*. 2021;73(9):e1231-e1241.

## Amikacin Dosing

23. **Zelenitsky S, et al.** Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. *Clinical Infectious Diseases*. 2009;48(12):1712-1721.

24. **Rea RS, et al.** Suboptimal aminoglycoside dosing in critically ill patients. *Therapeutic Drug Monitoring*. 2008;30(6):674-681.

25. **Bauer LA.** Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Education; 2014.

## Therapeutic Drug Monitoring (TDM)

26. **Roberts JA, et al.** Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. *International Journal of Antimicrobial Agents*. 2010;36(4):332-339.

27. **Abdul-Aziz MH, et al.** Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. *Intensive Care Medicine*. 2020;46(6):1127-1153.

28. **Gonzalez D, et al.** Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. *Clinical and Translational Science*. 2017;10(6):443-454.

## Pharmacokinetic-Pharmacodynamic (PK/PD) Modeling

29. **Craig WA.** Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clinical Infectious Diseases*. 1998;26(1):1-10.

30. **Mouton JW, et al.** Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. *Journal of Antimicrobial Chemotherapy*. 2005;55(5):601-607.

31. **Drusano GL.** Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. *Nature Reviews Microbiology*. 2004;2(4):289-300.

## Software and Tools

32. **Jelliffe R, et al.** Pmetrics: R package for pharmacometric modeling. *Journal of Pharmacokinetics and Pharmacodynamics*. 2014;41(5):431-443.

33. **Neely MN, et al.** PrecisePK: A Web-Based Tool for Individualized Vancomycin Dosing. *Clinical Infectious Diseases*. 2018;67(11):1773-1775.

34. **TDMx.** Therapeutic Drug Monitoring Expert System. Available at: https://www.tdmx.eu/

35. **NONMEM.** Nonlinear Mixed Effects Modeling. Available at: https://nonmem.iconplc.com/

## Deep Learning and Neural Networks

36. **Rajkomar A, et al.** Scalable and accurate deep learning with electronic health records. *NPJ Digital Medicine*. 2018;1(1):18.

37. **Beam AL, et al.** Clinical Machine Learning in Action: Challenges and Opportunities. *NPJ Digital Medicine*. 2020;3(1):1-4.

38. **Chen T, Guestrin C.** XGBoost: A Scalable Tree Boosting System. *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. 2016:785-794.

39. **Ke G, et al.** LightGBM: A Highly Efficient Gradient Boosting Decision Tree. *Advances in Neural Information Processing Systems*. 2017:3146-3154.

## Uncertainty Quantification

40. **Gal Y, Ghahramani Z.** Dropout as a Bayesian Approximation: Representing Model Uncertainty in Deep Learning. *Proceedings of the 33rd International Conference on Machine Learning*. 2016:1050-1059.

41. **Lakshminarayanan B, et al.** Simple and Scalable Predictive Uncertainty Estimation using Deep Ensembles. *Advances in Neural Information Processing Systems*. 2017:6402-6413.

## Clinical Decision Support Systems

42. **Sutton RT, et al.** An overview of clinical decision support systems: benefits, risks, and strategies for success. *NPJ Digital Medicine*. 2020;3(1):17.

43. **Kawamoto K, et al.** Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. *BMJ*. 2005;330(7494):765.

44. **Musen MA, et al.** Clinical decision-support systems. *Biomedical Informatics*. 2014:643-674.

## Regulatory and Ethical Considerations

45. **FDA.** Software as a Medical Device (SaMD): Clinical Evaluation. *FDA Guidance Document*. 2017.

46. **FDA.** Artificial Intelligence and Machine Learning in Software as a Medical Device. *FDA Discussion Paper*. 2019.

47. **EU MDR.** Regulation (EU) 2017/745 on medical devices. *European Union*. 2017.

48. **Char DS, et al.** Implementing Machine Learning in Health Care — Addressing Ethical Challenges. *New England Journal of Medicine*. 2018;378(11):981-983.

## Review Articles and Meta-Analyses

49. **Darwich AS, et al.** Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Future Perspectives on Individualization of Drug Therapy. *Annual Review of Pharmacology and Toxicology*. 2021;61:225-245.

50. **Keutzer L, et al.** Machine Learning for Model-Informed Precision Dosing: A Review of the State of the Art. *Clinical Pharmacokinetics*. 2021;60(11):1421-1437.

51. **Vandael E, et al.** Machine Learning for Clinical Decision Support in Infectious Diseases: A Narrative Review of Current Applications. *Clinical Microbiology and Infection*. 2020;26(5):584-595.

## Open Source Datasets and Repositories

52. **MIMIC-III.** Medical Information Mart for Intensive Care III. Available at: https://mimic.physionet.org/

53. **eICU.** eICU Collaborative Research Database. Available at: https://eicu-crd.mit.edu/

## Additional Resources

54. **ASHP.** American Society of Health-System Pharmacists. Available at: https://www.ashp.org/

55. **IDSA.** Infectious Diseases Society of America. Available at: https://www.idsociety.org/

56. **PK/PD Society.** Population Approach Group in Europe (PAGE). Available at: https://www.page-meeting.org/

57. **ACCP.** American College of Clinical Pharmacy. Available at: https://www.accp.com/

## Citation Format

When citing these references, please use appropriate citation styles (e.g., Vancouver, APA, or journal-specific formats).

## Last Updated

This references document was last updated in 2024. Please check for more recent publications and guidelines.

## Contributing References

If you have additional relevant references, please contribute them through pull requests or issues.

## Disclaimer

This list of references is provided for informational purposes only. The inclusion of a reference does not imply endorsement of the methods or conclusions described therein. Readers should evaluate each reference independently and in the context of their specific research or clinical application.

